We’re at the forefront of clinical and technical advancements. Our skilled and dedicated physicians have established clinical programs and conducted research that have kept the University of Minnesota at the forefront of clinical and technical advancements in interventional cardiology for decades, benefiting many patients in Minnesota and beyond.
TAVR Program Gives Hope to Inoperable Patients
The University’s new, groundbreaking Transcatheter Aortic Valve Replacement (TAVR) Program integrates multiple disciplines to provide a revolutionary treatment for patients with inoperable aortic stenosis.
In the first eight months of the program, 20 patients have successfully received this therapy, giving them a chance at a new life.
In September 2010, a randomized multicenter trial evaluated treatment methods for patients with inoperable aortic stenosis. The trial compared standard medical therapy to Transcatheter Aortic Valve Implantation (TAVI). The results demonstrated a 46 percent reduction in all-cause mortality and a 61 percent reduction in cardiovascular mortality at 24 months with treatment by TAVR. Based on these findings, the FDA approved the Edwards-Sapien TAVI in patients with inoperable aortic stenosis.
Shortly following the release of the Edwards-Sapien TAVI, we put together a TAVR team to provide this groundbreaking treatment. Our team consists of interventional cardiologists, echocardiographers, CT cardiologists, CV surgeons, vascular surgeons, anesthesia team, and core staff from the cardiac catheterization laboratory and operating room.